Menu
Supporting up to 70% of clinical decisions. A massive global market, combined with an ongoing desire to detect diseases as early as possible, makes novel diagnostic technology a highly fertile area for investment.
Glyconics® are supporters of patient involvement and advocating patient self-care and self-monitoring. We are pioneers of a new generation of diagnostics that can identify disease biomarkers in minutes at point-of-care and enable patients and physicians to work together in monitoring disease progression.
Glyconics® exploits the ability of Infrared light to produce distinctive molecular ‘fingerprints’ for healthy vs non-healthy samples. This is the first time IR Spectroscopy has been miniaturised to deliver accurate results in minutes.
Glyconics® is developing a range of proprietary handheld hardware devices with integrated algorithms for use at point-of-care to produce results in minutes.
Health providers globally are demanding improved Point of Care diagnosis. We are initially targeting Chronic Obstructive Pulmonary Disease (COPD) & Diabetes, the third and seventh causes of death worldwide and others to follow.
Diabetes is a major public health problem worldwide. Current global estimates indicate that this condition affects 425 million people and >50% remain undiagnosed.
We would love to tell you more about Glyconics® and our investment opportunities. Please call or email to arrange a visit to meet our team and see our groundbreaking technology for yourself.
Glyconics news, articles and featured posts.
Award-winning medtech firm, Glyconics has secured £1.5million in an Enterprise Investment Scheme (EIS) funding round ahead of a series A round next year.
Innovative diagnostics company, Glyconics® has been awarded an internationally recognised quality certification for the design and development of its medical devices product range.
World’s first hand-held infrared devices for COPD and other conditions to be produced following Glyconics agreement with Spectrolytic
Award-winning medtech firm, Glyconics© has secured internationally renowned diabetes expert, Dr Päivi Paldánius as the company’s first ever Chief Medical Officer (CMO) as the team ramps up and prepares to progress to its next clinical phase before embarking on a Series A funding round next year.
Innovative diagnostics company, Glyconics, has won an £85,000 Phase 1 grant from the Global Challenges Research Fund (GCRF) to explore the feasibility of implementing a novel low-cost point-of-care diagnostic platform for diabetic screening in developing countries.
The innovative diagnostics startup, with offices in Cambridge, Norwich and Basingstoke, raised well over the intended £850k in a raise led by investment platform Wealth Club plus existing investors Deepbridge Capital and Boundary Capital.